NCT06174064

BroadBand Light for the Treatment of Dry Eye Disease

Broadband Light for the Treatment of Dry Eye Disease and Meibomian Gland Dysfunction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The investigators will be evaluating the use of broadband light in Dry Eye and Meibomian Gland Dysfunction.

Detailed description

Broadband light (BBL) is a widely used treatment for improvement of inflammatory dermatologic conditions such as acne and rosacea, and may have similar therapeutic benefits on the treatment of dry eye disease by targeting inflammation of the eyelids. The investigators propose a prospective study to determine the safety and efficacy of BBL treatment on patients with dry eye disease and meibomian gland dysfunction. Each participant will have three treatments of BBL at monthly intervals to the cheek and periorbital area with subsequent follow up. Measured endpoints will include signs and symptoms of dry eye control including full ophthalmic exam, dry eye diagnostic testing, photographs, and standardized questionnaires.

Conditions

• Dry Eye Syndromes
• Meibomian Gland Dysfunction

Interventions

Type	Name	Description
DEVICE	Broadband Light treatment	While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
DEVICE	Sham broadband light treatment	The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-07-01
• Completion: 2025-08-30
• First posted: 2023-12-18
• Last updated: 2023-12-18

Regulatory

• FDA-regulated device study